Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Buy
75
BIOGY Quote, Financials, Valuation and Earnings
Last price:
$10.35
Seasonality move
:
5.31%
Day range:
$10.35 - $10.35
52-week range:
$8.79 - $11.50
Dividend yield:
6.79%
P/E ratio:
33.64x
P/S ratio:
7.25x
P/B ratio:
8.39x
Volume:
--
Avg. volume:
200
1-year change:
-10%
Market cap:
$1B
Revenue:
$134.6M
EPS (TTM):
$0.31
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, BioGaia AB has -- downside to fair value with a price target of -- per share.
BIOGY vs. S&P 500
-
Over the past 5 trading days, BioGaia AB has overperformed the S&P 500 by 0.63% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioGaia AB does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioGaia AB has grown year-over-year revenues for 2 quarters straight. In the most recent quarter BioGaia AB reported revenues of $34.3M.
Earnings Growth
-
BioGaia AB has grown year-over-year earnings for 1 quarter straight. In the most recent quarter BioGaia AB reported earnings per share of $0.07.
Enterprise value:
969.6M
EV / Invested capital:
7.49x
Price / LTM sales:
7.25x
EV / EBIT:
23.65x
EV / Revenue:
6.72x
PEG ratio (5yr expected):
--
EV / Free cash flow:
30.11x
Price / Operating cash flow:
32.52x
Enterprise value / EBITDA:
22.27x
Gross Profit (TTM):
$105M
Return On Assets:
17.64%
Net Income Margin (TTM):
21.57%
Return On Equity:
20.94%
Return On Invested Capital:
20.94%
Operating Margin:
27.54%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $119.9M | $128.6M | $144.4M | $29.2M | $34.3M | |
| Gross Profit | $87.8M | $94.6M | $105M | $21.3M | $25.5M | |
| Operating Income | $40.3M | $38.6M | $41M | $4.4M | $9.5M | |
| EBITDA | $42.7M | $45.9M | $43.5M | $10M | $10.1M | |
| Diluted EPS | $0.41 | $0.32 | $0.31 | $0.03 | $0.07 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $199.2M | $155.7M | $168.9M | $147.6M | $116.9M | |
| Total Assets | $224.9M | $194.8M | $212.1M | $187.9M | $158.1M | |
| Current Liabilities | $11.9M | $15.6M | $20M | $19M | $18.6M | |
| Total Liabilities | $14.7M | $28.2M | $29.4M | $28.1M | $28.6M | |
| Total Equity | $210.2M | $166.6M | $182.7M | $159.8M | $129.5M | |
| Total Debt | $1.6M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $36.9M | $36.9M | $32.5M | $9.5M | $11.5M | |
| Cash From Investing | -$3.4M | -$2.6M | -$326.4K | -$266.3K | -$109.2K | |
| Cash From Financing | -$27.7M | -$65.6M | -$72M | $1.3M | -$2.1M | |
| Free Cash Flow | $33.8M | $34.3M | $32.2M | $9.2M | $11.4M | |
BIOGY
Sector
Market Cap
$1B
--
Price % of 52-Week High
90%
--
Dividend Yield
6.79%
--
Shareholder Yield
6.24%
--
1-Year Price Total Return
-10%
--
Beta (5-Year)
0.447
--
Dividend yield:
6.79%
Annualized payout:
$0.64
Payout ratio:
-250.12%
Growth streak:
1 years
Technicals
8-day SMA
Sell
Level
$10.35
200-day SMA
Buy
Level
$10.04
Bollinger Bands (100)
Buy
Level
9.51 - 10.87
Chaikin Money Flow
Buy
Level
185.9K
20-day SMA
Buy
Level
$10.15
Relative Strength Index (RSI14)
Buy
Level
61.07
ADX Line
Buy
Level
34.12
Williams %R
Sell
Level
0
50-day SMA
Sell
Level
$10.46
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Sell
Level
-172.7K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (24.2203)
Buy
CA Score
(Annual)
Level (2.2822)
Sell
Beneish M-Score
(Annual)
Level (-2.0799)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-5.0019)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, oral rehydration solutions, digestive health tablets, and also royalties pertaining to pediatric products. The Adult Health segment include gut health tablets, oral health products, and offers cultures as an ingredient in a licensee's dairy product. The Other segment consists royalties from the development projects, and revenue from packaging solutions. The company was founded by Jan Annwall and Peter Michael Rothschild in 1990 and is headquartered in Stockholm, Sweden.
Stock Forecast FAQ
In the current month, BIOGY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BIOGY average analyst price target in the past 3 months is --.
-
Where Will BioGaia AB Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioGaia AB share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About BioGaia AB?
Analysts are divided on their view about BioGaia AB share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioGaia AB is a Sell and believe this share price will rise from its current level to --.
-
What Is BioGaia AB's Price Target?
The price target for BioGaia AB over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BIOGY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioGaia AB is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BIOGY?
You can purchase shares of BioGaia AB via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioGaia AB shares.
-
What Is The BioGaia AB Share Price Today?
BioGaia AB was last trading at $10.35 per share. This represents the most recent stock quote for BioGaia AB. Yesterday, BioGaia AB closed at $10.35 per share.
-
How To Buy BioGaia AB Stock Online?
In order to purchase BioGaia AB stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get BIOGY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BIOGY
Sector
P/E ratio
33.64x
--
PEG ratio
--
--
P/B ratio
8.39x
--
Price / LTM sales
7.25x
--
Growth Metrics
BIOGY
Sector
Revenue growth
17.67%
--
Earnings growth
97.12%
--
Revenue (5-year growth)
10.63%
--
Earnings forecast
--
--
Profitability
BIOGY
Sector
Profitability FY 2024
$96.8M
--
Return on invested capital
20.94%
--
Return on assets
17.64%
--
Return on equity
20.94%
--
Earnings Date
Last Earnings Date
Oct
22
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Jan
21
Balance Sheet
BIOGY
Sector
Total cash
$77.4M
--
Short term investments
--
--
Total assets
$184.1M
--
Long term debt
--
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 3.51% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 1.79% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 5.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
